The critical impact of respiratory and physical therapists in the management of bronchiectasis is emphasized.
This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on the bronchiectasis management team.
While the overseeing physician directs evaluations and treatments, an integrated team approach is critical for optimizing bronchiectasis care. Respiratory therapists play vital roles teaching effective airway clearance techniques and devising regimens fitting patient lifestyles to promote adherence. Nurses also provide airway clearance education and self-management training. Physical therapists contribute through pulmonary rehabilitation for qualifying patients.
Infectious disease input helps guide complex infections like highly resistant organisms or unusual nontuberculous mycobacteria. Underlying disorders like cystic fibrosis or primary ciliary dyskinesia occur occasionally, requiring tailored approaches.
Access to genetic counseling is necessary when primary ciliary dyskinesia is suspected. Ultimately, an experienced coordinator facilitating communications/follow-up and assisting troubleshooting maximizes outpatient care quality. An integrated, multidisciplinary care team is essential for delivering comprehensive, high value bronchiectasis care.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More